A Prospective, Multicenter, Single-Arm, Open-Label, Phase 3 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging. (RESTORE)

drug protocol number
67896049PAH4005
drug sponsor
Selexipag
drug study
Selexipag
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Completed
drug phase